ArticleWorld journal of surgical oncology2025
Mutational landscape of gastrointestinal stromal tumors using next-generation sequencing of a 73-gene panel.
Article in World journal of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeMutational analysis guides therapeutic decision-making for patients with advanced-stage gastrointestinal stromal tumors (GISTs). MATERIALS AND
methodsA total of 491 patients with GISTs were retrospectively included, and their genomic profiles were determined by targeted NGS of 73 or 1,021 gene panels.
resultsKIT mutations were identified in 84.7% (416/491) of patients with GISTs, and PDGFRA mutations were identified in 4.5% (22/491) of patients. Among the patients with KIT mutant-GISTs, most had KIT mutations in exon 11 (81.3%, 338/416). PDGFRA mutations were located mainly in exon 18 (77.3%, 17/22). In the remaining 11% of patients with GISTs without KIT or PDGFRA mutations (wild-type GISTs), BRAF and NF1 were the most commonly mutated genes. Compared with KIT/PDGFRA-mutant GISTs, wild-type GISTs were associated with younger age, a greater proportion of female patients, and lower levels of copy number variations. Notably, the concomitant alterations of KIT/PDGFRA-mutant or wild-type GISTs were similar when sequencing data from a 73-gene panel and a 1,021-gene panel were analyzed. The genetic landscape of patients with treatment-naïve GISTs at different locations was described by using a 73-gene panel, and compared with patients with gastric GISTs, patients with nongastric GISTs had higher levels of copy number variations but a lower proportion of PDGFRA mutations. Analysis of the genomic profiles before and after imatinib treatment revealed KIT T670I mutation, as well as ATM and JAK2 mutations, as potential underlying mechanisms of resistance.
conclusionUsing a 73-gene panel, we characterized the molecular characteristics of GISTs and revealed a correlation with their clinical features. Moreover, KIT/PDGFRA-dependent and KIT/PDGFRA-independent mechanisms underlying resistance to imatinib were explored. Overall, our 73-gene panel is sufficient for clinical application in cases of GISTs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.